GSK "to pay $460 million" to settle bulk of US Avandia claims out of a total $2.4 billion Q2 legal bill
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has reportedly agreed to pay around $460 million to resolve around 10,000 Avandia (rosiglitazone) lawsuits (out of the roughly 11,000 suits outstanding) from US patients or family members alleging that use of the product led to injury, according to the Bloomberg news service, citing people familiar with the accords. The figure pales next to the $2.36 billion GSK said it expected to record in legal charges during the second quarter in a statement released today by the pharma giant.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.